A gene transfer approach to treating the bleeding disorder hemophilia B remains safe and effective long-term, as scientists ...

It was found that those with severe hemophilia B have less than 1% of normal factor IX activity, often experiencing spontaneous bleeding that can cause joint damage or life-threatening events.

In a 13-year follow-up by St. Jude Children’s Research Hospital and University College London published in The New England ...

A gene transfer approach to treating the bleeding disorder hemophilia B remains safe and effective long-term, as scientists from St. Jude Children's ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Hemophilia A Market Trends The report provides a detailed analysis of the current hemophilia A marketed drugs and late-stage pipeline drugs ...

The results of gene therapy for hemophilia B contrast with those of factor replacement therapies, where lifelong infusions ...

Aug. 29, 2024 — For decades, scientists have dreamt of a future where genetic diseases, such as the blood clotting disorder hemophilia, could be a thing of the past. Gene therapy, the idea of ...

Revolutionary advancements in blood cancer treatment, from targeted therapy to gene editing, promise more effective and ...

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion. The approval ...

Learn how clotting factor therapy, gene therapy, and non-factor treatments are improving hemophilia prognosis and life expectancy.